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Objective: This study assesses the performance of noninvasive prenatal testing (NIPT) for fetal aneu-
ploidies in a mixed risk factors pregnancy population.
Materials and methods: Data review of 169 pregnant women undergoing prenatal aneuploidy screening
in a single tertiary medical center was conducted. Indications included maternal anxiety, advanced
maternal age, abnormal nuchal translucency, and high/moderate risk of ﬁrst trimester Down syndrome
screening. Multifetal pregnancies and patients receiving in vitro fertilization were also enrolled for
analysis.
Results: A total of 169 patients were enrolled in this study during a time period from July 2012 to June
2014. For patients'  34 years, anxiety about amniocentesis was the most common reason for patients
selecting NIPT for fetal aneuploidy screening, with 107 (88.4%) patients choosing NIPT for this reason.
Among the total patient population, two patients showed a positive result from NIPT. One patient dis-
played 47, XXY, which was conﬁrmed to be a false-positive result. The other patient displayed trisomy 18,
which was conﬁrmed by an amniotic cell culture. The sensitivity for NIPT is 100% with the speciﬁcity
99.4%.
Conclusions: NIPT for fetal aneuploidy in a mixed risk factors pregnancy population showed high ac-
curacy. NIPT applied to the low risk population might reassure the anxious family.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Prenatal screening for fetal aneuploidy is a standard offering in
most parts of the world. Fetal aneuploidies, such as trisomy 21 (T21,
Down syndrome), trisomy 18 (T18, Edwards syndrome), and tri-
somy 13 (T13, Patau syndrome), as well as aneuploidies related to
the X and Y chromosomes are the most common chromosomal
abnormalities. Using the ﬁrst trimester screening (FTS), consisting
of maternal serum markers and nuchal translucency (NT) mea-
surement, we were able to identify 85e95% of T21 and T18 cases,
with a 5% rate of false positives. Invasive procedures, amniocentesisand Gynecology, Taipei Vet-
, Taipei 11217, Taiwan.
en).
bstetrics & Gynecology. Publishedand chorionic villus sampling were taken as diagnostic tools [1,2].
The discovery of the presence of fetal cell-free DNA (cfDNA) and
RNA in maternal plasma, combined with new DNA sequencing
technology, has allowed noninvasive prenatal testing (NIPT) of
common fetal trisomy with high sensitivity and speciﬁcity. From a
multicenter prospective cohort study, NIPT provided detection
rates > 99% for T21 and false-positive rates < 0.1% [3].
Due to the high accuracy of this new technology, the Interna-
tional Society for Prenatal Diagnosis, the National Society of Genetic
Counselors, the American College of Obstetricians and Gynecolo-
gists (ACOG), and the Society for MaternaleFetal Medicine (SMFM)
have published committee opinions stating that cfDNA testing
could be offered to pregnant women at high risk for fetal aneu-
ploidy as a screening option after counseling [4e6]. Therefore, this
technology might reduce the number of unnecessary invasive
procedures, compared with conventional maternal serumby Elsevier Taiwan LLC. All rights reserved.
Table 1
Maternal characteristics and gestational age of blood sampling.
Maternal age
Median (y): 35.31
Advanced maternal age ( 34 y old): 121 (71.6%)
 28 y old (n, %): 4 (2.5%)
29e33 y old (n, %): 44 (26.2%)
34e38 y old (n, %): 90 (53.3%)
39e42 y old (n, %): 27 (15.9%)
 43 y old (n, %): 4 (2.5%)
Gestational age at blood sampling
Median (wk) 13.45 wk
Range (wk) 7e31 wk
6e8 wk (n, %) 3 (1.8%)
9e12 wk (n, %) 64 (39.3%)
13e16 wk (n, %) 74 (45.5%)
17e20 wk (n, %) 17 (10.4%)
21e24 wk (n, %) 3 (1.8%)
25e28 wk (n, %) 1 (0.6%)
>28 wk (n, %) 1 (0.6%)
History or family history of aneuploidies (n, %) 4 (2.4%)
Fig. 1. Indication of NIPTdpatients less than 34 years old.
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nology in a mixed risk factors group has not yet been fully assessed.
This study reports the ﬁnding from an observational study which
was carried out to assess the performance of NIPT for fetal aneu-
ploidy in a mixed risk factors pregnancy population.
Materials and methods
From July 2012 to June 2014, data were collected from a total of
169 pregnant women undergoing NIPT in a single tertiary medical
center. Indications included maternal anxiety, advanced maternal
age ( 34 years), abnormal NT, high/intermediate risk of maternal
serum screening (2 and 4 markers), and high/intermediate risk
result from ﬁrst trimester screening. Twin pregnancies (total
number 12), triplets (total number one), and patients receiving
artiﬁcial reproductive technology (ART) to conceive, were also
enrolled for analysis.
Result
A total of 169 pregnant women from a single tertiary medical
center were recruited in this study. Maternal age ranged from 27 to
44 years. Median age was 35.31 years and 71.6% (121/169) were 
34 years (Table 1). Thirty-one pregnant women had received ART,
including six with intrauterine insemination, 24 with in vitro
fertilization (IVF), and one with intracytoplasmic sperm injection
(ICSI) (Table 2). Four women had a history or family history of
aneuploidies.
Indication for NIPT
For patients < 34 years of age (48 patients) 27 (56.3%) asked for
NIPT due to anxious feelings of possible fetal aneuploidies. OtherTable 2
The ways of patients got conceived.
Method of conception Number of patients Percent (%)
IUI 6 3.6
IVF 24 14.2
IVF (ICSI) 1 0.6
Nature 138 81.7
Total 169 100.0
ICSI ¼ intracytoplasmic sperm injection; IUI ¼ intrauterine insemination;
IVF ¼ in vitro fertilization.indications included high risk of T13, T18, or T21, which accounted
for 10 patients (20.8%), and intermediate risk of T13, T18, or T21,
which accounted for another 10 patients (20.8%) (Fig. 1). For pa-
tients  34 years, anxiety about amniocentesis was the most
common reason for the patient selecting NIPT for fetal aneuploidy
screening, with 107 (88.4%) patients choosing NIPT for this reason.
Other indications included 7 (5.8%) patients of high risk of T13, T18,
or T21 and 7 (5.8%) patients of intermediate risk of T13, T18, or T21
(Fig. 2). For the 107 patients who were anxious about amniocen-
tesis, 24 (22.4%) had taken NIPT as a primary test and had neither
received FTS nor maternal serum screening (2 markers and 4
markers); 35 (32.7%) patients had taken NIPT before FTS; and 47
(43.9%) patients had taken NIPT and FTS on the same day.Fetal aneuploidies
Among 169 patients, two patients showed positive results from
NIPT. One showed positive for 47, XXY and the other showed pos-
itive for T18. Both later received amniocentesis for diagnostic
conﬁrmation. The patient who had the result of 47, XXY was later
shown to have a false-positive result. The fetus was conﬁrmed to be
46, XY using amniocentesis and was shown to be a healthy male
baby after delivery. The other patient, who showed positive for T18
from NIPT, went on to have amniocentesis which conﬁrmed the
diagnosis of T18. After diagnosis, the patient decided to terminate
the pregnancy.
The sensitivity for fetal aneuploidy screening in this study was
100% with a speciﬁcity of 99.4%.Discussion
Since Lo et al [7] discovered the presence of fetal DNA fragments
in maternal serum, a new technology for prenatal aneuploidyFig. 2. Indication of NIPTdpatients S 34 years old.
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NIPT and what group of patients should be offered NIPT is still
uncertain.Low risk group
This study examines data from a single tertiary medical center
where NIPT has been provided to patients since July 2012. Due to
the health insurance policy in Taiwan, prenatal aneuploidy
screening for patients < 34 years is not covered by national health
insurance. This means any screening in this age group is done under
self-payment. Some patients (n ¼ 27, 16% of total patients receiving
NIPT) were concerned with the accuracy of the maternal serum test
or FTS and opted to have amore accurate test. Despite it beingmore
expensive, they asked for NIPT. This practice is not recommended
according to the ACOG announcement in 2012. NIPT is only rec-
ommended for patients in a high risk group [6]. NIPT application to
the low risk group is still a matter of conﬂict; a study published in
2014 reported that 1914 women of general risk in the obstetric
population showed signiﬁcantly lower false-positive rates and
higher positive predictive values for detection of T21 and T18When
the physicians applied NIPT rather than traditional screening [8].Advanced maternal age group
For women > 34 years, national health insurance in Taiwan
covers part of the prenatal testing payment and makes amnio-
centesis much cheaper than NIPT, which must be paid fully by the
patient. Amniocentesis costs 8000 New Taiwan Dollars (NT) (265
US dollars), and NIPT costs around 24,000 NT (795 US dollars).
Nevertheless, 107 patients > 34 years selected NIPT for fetal
aneuploidy screening due to anxious feelings about amniocentesis.
Amniocentesis tests are highly accurate; however, they are associ-
ated with an iatrogenic miscarriage rate up to 1% [9]. As women of
advanced age ﬁnd it more difﬁcult to get pregnant, they are more
concerned with the potential risk of invasive procedures.Multifetal pregnancies
The current study did not exclude multiple gestations; there
were 12 twin pregnancies and one set of triplets. The results of NIPT
were all negative and conﬁrmed to be correct after birth. Although
the power of NIPT in multifetal pregnancies has not yet been
established, there have been several studies showing promising
results [10e12]. Themain problem for multifetal pregnancies is due
to the reporting rate of results being lower than in singleton
pregnancies due to a lower fetal fraction and also from the result
not being able to determine which baby is affected.ART group
Patients receiving ART to get pregnant were a special group of
patients who asked for NIPT. As many of these patients face the
problem of infertility and were paying a lot of money to get preg-
nant, they were keen to have a more accurate screening test,
despite the expense. In the current study, patients receiving ART
accounted for 18.3% (n ¼ 31) of all patients. Screening tests for
genetic problems for patients receiving IVF do not need to be NIPT
because preimplantation genetic screening or preimplantation
genetic diagnosis (PGS/PGD) are promising tools that can give re-
sults before getting pregnant. Methods may involve biopsy polar
bodies, blastomeres or trophoblast [13]. If patients have PGS/PGD,
the need for NIPT might disappear.The accuracy of NIPT
A sensitivity of NIPT of 100% with a speciﬁcity of 99.4% was
observed in this study. Two positive results were identiﬁed through
NIPT. One result was shown to be a false-positive result of 47, XXY.
The other result was a true-positive result of T18. Both patients
received amniocentesis for diagnosis. NIPT uses mathematical
calculation to “estimate the amount” of each chromosome.
Although numerous studies have already proven it more accurate
than conventional screening, it still has some restrictions. For
example, a fetal amount of at least 4% is necessary for an accurate
result; a lower level can cause false-negative results [3,14,15], false-
positive results can also occur. A low false-positive rate of < 1% was
observed in other studies [16e19]. Although quite low, this still
might cause unnecessary worries to the mother, or even amistaken
decision to have an abortion. Therefore, the ACOG and SMFM
announcement in 2012 suggests positive results of NIPT should be
followed by an invasive procedure to conﬁrm the diagnosis, which
we also agree is necessary [6].Conclusion
In conclusion, this study shows that NIPT had better perfor-
mance than conventional screening methods in the mixed risk
patient population study group. The use of NIPT in the low risk
population is feasible and might turn into a primary screening
method for fetal aneuploidy in the future. NIPT for multifetal
pregnancy can be considered as a choice for prenatal screening;
however, some limitations must be taken seriously and physicians
should have prenatal counseling with the patient before and after
the screening. Due to the small population of this study, further
investigation is needed.Conﬂicts of interest
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